Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Androstadienes
  • Antineoplastic Agents
  • Prostatic Neoplasms
  • Quality of Life
  • Taxoids

abstract

  • The previously demonstrated survival benefit for abiraterone is accompanied by improvements in patient-reported HRQoL and a significant delay in HRQoL deterioration when compared with prednisone.

publication date

  • November 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.ejca.2013.07.144

PubMed ID

  • 23973186

Additional Document Info

start page

  • 3648

end page

  • 57

volume

  • 49

number

  • 17